Method for treatment of disease by anti-TIGIT antibody in combination with PD-1 inhibitor and pharmaceutical combination

A PD-1 and inhibitor technology, applied in the direction of drug combination, antibody medical components, antibodies, etc., can solve the problem of disappearance

Active Publication Date: 2020-10-09
JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF33 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Chew et al. found that the combination of TIGIT antibody and PD-1 antibody can promote the killing function o

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treatment of disease by anti-TIGIT antibody in combination with PD-1 inhibitor and pharmaceutical combination
  • Method for treatment of disease by anti-TIGIT antibody in combination with PD-1 inhibitor and pharmaceutical combination
  • Method for treatment of disease by anti-TIGIT antibody in combination with PD-1 inhibitor and pharmaceutical combination

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0174] Embodiment 1, the preparation of TIGIT antigen antibody

[0175] 1.1 Protein design and expression

[0176] Using human TIGIT protein (Uniprot number: Q495A1) as the template of TIGIT of the present disclosure, design the amino acid sequence of the antigen and detection protein of the present disclosure, optionally fuse different tags on the basis of TIGIT protein, and clone them respectively on the pHr vector ( Self-produced) or pXC-17.4 vector (LONZA), transiently expressed in 293 cells or stably expressed and purified in CHO cells, to obtain the protein encoding the disclosed antigen and detection. The following TIGIT antigens refer to human TIGIT unless otherwise specified.

[0177] Fusion protein of TIGIT extracellular region and mouse IgG2aFc fragment: TIGIT-mFc, for immunization and detection

[0178] MEFGLSWLFLVAILKGVQC MMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIPEPRGPTIKPCPPCKCPAPNL...

Embodiment 2

[0197] Embodiment 2, preparation of anti-human TIGIT hybridoma monoclonal antibody

[0198] 2.1 Immunity

[0199] Anti-human TIGIT monoclonal antibody was produced by immunizing mice. SJL white mice used in the experiment, female, 6-8 weeks old (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., animal production license number: SCXK (Beijing) 2012-0001). Breeding environment: SPF grade. After the mice were purchased, they were raised in a laboratory environment for 1 week, with a 12 / 12 hour light / dark cycle adjustment, a temperature of 20-25° C., and a humidity of 40-60%. The acclimatized mice were immunized according to the following scheme. The immunizing antigen is the extracellular region of human TIGIT with mFc (SEQ ID NO: 1).

[0200] Immunization regimen: with Gold Adjuvant (Sigma Cat No.T2684) and Thermo Alum (Thermo Cat No.77161) adjuvant cross-immunization. Antigen and adjuvant ( Gold Adjuvant) ratio of 1:1, antigen and adjuvant (Thermo Alu...

Embodiment 3

[0242] Example 3, Humanization of mouse-derived anti-human TIGIT antibody

[0243] By comparing the IMGT human antibody heavy and light chain variable region germline database and MOE software, the heavy chain and light chain variable region germline genes with high homology to the mouse antibody were selected as templates, and the mouse antibody The CDRs are respectively transplanted into corresponding human templates to form variable region sequences in the order of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Back-mutation was carried out on the amino acids in the FR region as required to obtain a humanized anti-TIGIT monoclonal antibody. In the following exemplary specific examples, the determination of the amino acid residues in the CDR region is determined and annotated by the Kabat numbering system.

[0244] The light and heavy chain variable regions of the above murine antibodies are linked with the light and heavy chain constant regions of the human antibody to form a chimeric an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure relates to a method for treatment of disease by an anti-TIGIT antibody in combination with a PD-1 inhibitor and pharmaceutical combinations. Further, the present disclosure relates to the treatment of human TIGIT-related diseases (e.g., tumors) in combination with a PD-1 inhibitor (e.g., an anti-PD-1 antibody) with a drug of an anti-TIGIT antibody or an antigen-binding fragment thereof.

Description

technical field [0001] The present disclosure relates to methods and drug combinations for treating diseases with anti-TIGIT antibodies combined with PD-1 inhibitors. Background technique [0002] The statements herein merely provide background information related to the present invention and do not necessarily constitute prior art. [0003] In recent years, immune checkpoint therapy targeting immune cell co-inhibitory receptors has made great progress in tumor immunotherapy, and the discovery and verification of new co-inhibitory receptors has become a global competitive hotspot. T cells are the key mediators of the immune response, and the activation of T cells depends on TCR signaling and co-stimulatory signals. Co-stimulatory signals are limiting signals for T cell activation, and their dysfunction is involved in the occurrence of autoimmune diseases (Immunol Rev, 2012, 248:122-139; AutoimmunRev, 2013, 12: 1171-1176). TIGIT (T cell immunoglobulin and ITIM domain) is a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K39/395A61P35/00A61P35/02A61P37/02A61P31/00C07K16/28
CPCA61K45/06A61K39/39533A61P35/00A61P35/02A61P37/02A61P31/00C07K16/2803A61K2039/507C07K2317/56C07K2317/565C07K2317/24C07K2317/92C07K2317/76A61K2300/00
Inventor 付雅媛许志宾陶维康
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap